Myriad’s BRACAnalysis CDx® Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes from Pfizer's PARP ...
SALT LAKE CITY, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that data from the EMBRACA trial showed Myriad’s BRACAnalysis CDx® test successfully …